



## **Outcome-Based Contracts for Pharmaceutical Products: Opportunities and Challenges**

**September 8, 2016**

**W Hotel, 515 15th Street NW, Washington, DC, 20004**

Payers are expanding payment models that emphasize value over volume of services and are now starting to establish value-based arrangements for pharmaceuticals. In the past year, payers and pharmaceutical firms have announced outcome-based contracts for high cholesterol, heart failure and diabetes drugs. This roundtable will discuss the objectives, approaches and structures of recent value-based contracts. It will then discuss challenges to implementing these arrangements, potential solutions and the future outlook for value-based contracting for pharmaceuticals. The session will conclude with a special luncheon session on key issues and future directions for the FDA.

**8:30 a.m. Coffee and Continental Breakfast**

**9:00 a.m. Welcome and Introduction**

Stuart Altman, Ph.D., Professor of National Health Policy, Brandeis University

**9:15 a.m. Value-Based Contracting for Pharmaceuticals – Purchaser Perspective**

Chris Bradbury, Senior Vice President, Cigna Pharmacy Management

**9:45 a.m. Discussion**

**10:30 a.m. Break**

**10:45 a.m. Value-Based Contracting for Pharmaceuticals – Pharmaceutical Firm Perspective**

Amy Rudolph, VP Health Economics and Outcomes Research, Novartis  
Pharmaceuticals

**11:15 a.m. Discussion**

**12:00 p.m. Lunch**

**12:30 p.m. Accomplishments, Challenges and Future Directions for the FDA**

Margaret Hamburg MD, Former Commissioner, US Food and Drug Administration

**2:00 p.m. Meeting adjourns**